ADC Review / Journal of Antibody-drug Conjugates

ADC Review / Journal of Antibody-drug Conjugates ADC Review | Journal of Antibody-Drug Conjugates is an Open Access hybrid, peer reviewed publication. The publication includes a Social Media (peer-to-peer) shell with a controlled but freely accessible Open Access peer review journal.

Operating as usual

Robust development and manufacturing solutions for your ADCs.
12/17/2020
Robust development and manufacturing solutions for your ADCs

Robust development and manufacturing solutions for your ADCs.

Robust development and manufacturing solutions for your ADCs Robust Development and Manufacturing Solutions for your ADCs Greetings! Antibody Drug Conjugates (ADCs) are one of the fastest growing ther

The Onco'Zine Newsletter: 5 Things you May have Missed Last Month.  Click to read: https://conta.cc/3h76gBwClick on the ...
09/09/2020

The Onco'Zine Newsletter: 5 Things you May have Missed Last Month. Click to read: https://conta.cc/3h76gBw

Click on the link below to sign up to receive our newsletter (Onco'Zine and ADC Review | Journal of Antibody-drug Conjugates):

https://conta.cc/32c3yq8

With 9 FDA-approved and commercially available ADCs, and many more in clinical development, It's important to stay up to...
09/07/2020

With 9 FDA-approved and commercially available ADCs, and many more in clinical development, It's important to stay up to date with news about Antibody-drug Conjugates. Sign up for the ADC Review newsletter: https://conta.cc/3gMvdT4

Are you interested in the latest news about the advances in the development of Antibody-drug Conjugates (ADCs) in the tr...
08/31/2020
Sign Up

Are you interested in the latest news about the advances in the development of Antibody-drug Conjugates (ADCs) in the treatment of patients with cancer or hematological malignancies? Are you interested in learning about the development of ADCs beyond cancer?

If so, sign up for the ADC Review | Journal of Antibody-drug Conjugates Newsletter at

https://lnkd.in/eyR5Y3b

The Newsletter is developed by the Publishers of ADC Review | Journal of Antibody-drug Conjugates and Onco'Zine.

Sign Up Here!

Stay up-to-date with R&D and regulatory updates of Antibody-drug Conjugates (ADC) in HemOnc. Click on the link to sign u...
08/07/2020

Stay up-to-date with R&D and regulatory updates of Antibody-drug Conjugates (ADC) in HemOnc. Click on the link to sign up for our Newsletter!

https://adc.expert/newsletterandwebinars

@ASCO @AACR @CPhIww #oncoogy #hematology @myESMO @AAPSonline @AAPSComms #pharma @world_ADC

Sign Up for the ADC Review | Journal of Antibody-drug Conjugates Newsletter.Stay on top of the latest developments invol...
07/02/2020
Sign Up

Sign Up for the ADC Review | Journal of Antibody-drug Conjugates Newsletter.

Stay on top of the latest developments involving Antibody-drug Conjugates.

Enjoy a selection of the most-read articles published in ADC Review | Journal of Antibody-drug Conjugates, handpicked by our editorial team. When you sign up for our mailing list, you'll also receive our overview of scheduled educational webinar presentations.

https://adc.expert/newsletterandwebinars

#ADC #antibodydrugconjugate #drugdevelopment #webinars #medicaleducation #cancer #cancertreatment #beyondcancer

Sign Up Here!

In an episode of The Onco'Zine Brief, Peter Hofland talks with Thorsten Sperber, Global Head Medical Affairs at Immunome...
06/17/2020

In an episode of The Onco'Zine Brief, Peter Hofland talks with Thorsten Sperber, Global Head Medical Affairs at Immunomedics.

Hofland and Sperber talk about sacituzumab govitecan, a novel antibody-drug conjugate. At the time of this interview, the drug was not yet approved, but in the weeks following the interview, the U.S. Food and Drug Administration (FDA) approved sacituzumab govitecan (Trodelvy™) for the treatment of adult patients with metastatic triple-negative breast cancer

https://lnkd.in/gw7RBkq

https://www.spreaker.com/user/7078249/tob-sacituzumab-govitecan-mtnbc-001

Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trialhttps://www.adc...
06/13/2020
Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial » ADC Review

Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial

https://www.adcreview.com/news/loncastuximab-tesirine-demonstrates-an-high-response-rates-in-pivotal-phase-ii-single-agent-trial/

AACR Foundation American Association of Pharmaceutical Scientists (AAPS) CPhI

Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial » ADC Review

Beyond Oncology: ABBV-3373 Shows Improvement in Disease Activity in Phase IIa Study in Rheumatoid Arthritishttps://www.a...
06/12/2020
Beyond Oncology: ABBV-3373 Shows Improvement in Disease Activity in Phase IIa Study in Rheumatoid Arthritis » ADC Review

Beyond Oncology: ABBV-3373 Shows Improvement in Disease Activity in Phase IIa Study in Rheumatoid Arthritis

https://www.adcreview.com/news/beyond-oncology-abbv-3373-shows-improvement-in-disease-activity-in-phase-iia-study-in-rheumatoid-arthritis/

#rheumatoid #arthritis #antibodydrugconjugate #research #immunotherapy #clinicaltrial #ADC

CPhI American Association of Pharmaceutical Scientists (AAPS) AbbVie Careers Genmab

Beyond Oncology: ABBV-3373 Shows Improvement in Disease Activity in Phase IIa Study in Rheumatoid Arthritis » ADC Review

Abbvie and Genmab Sign $ 3.9 Billion Agreement to develop next-gen bispecific antibody programs, epcoritamab, DuoHexaBod...
06/12/2020
AbbVie and Genmab Sign U.S. $ 3.9 Billion Development Agreement » ADC Review

Abbvie and Genmab Sign $ 3.9 Billion Agreement to develop next-gen bispecific antibody programs, epcoritamab, DuoHexaBody®-CD37, and DuoBody-CD3x5T4.

https://www.adcreview.com/business-economics/abbvie-and-genmab-sign-u-s-3-9-billion-development-agreement/

AACR Foundation American Association of Pharmaceutical Scientists (AAPS) CPhI

AbbVie and Genmab Sign U.S. $ 3.9 Billion Development Agreement » ADC Review

[WEBINAR] Spaces are filling up fast for our webinar on Tuesday, May 26th at 11:00 am PDT /2:00 pm EDT.Reserve your spot...
05/25/2020

[WEBINAR] Spaces are filling up fast for our webinar on Tuesday, May 26th at 11:00 am PDT /2:00 pm EDT.

Reserve your spot today and join us for a WEBINAR discussing TRPH-222 Preclinical Development and Interim Phase I Data: Enhancing Clinical Safety and Overcoming ADC Manufacturing Challenges with SMARTag® Technology

Click on the link to register:

http://www.adc.expert/trph222-webinar

Join us for a WEBINAR discussing TRPH-222 Preclinical Development and Interim Phase I Data: Enhancing Clinical Safety an...
05/21/2020

Join us for a WEBINAR discussing TRPH-222 Preclinical Development and Interim Phase I Data: Enhancing Clinical Safety and Overcoming ADC Manufacturing Challenges with SMARTag® Technology

Tuesday, May 26, 2020 at 11.00 am (PDT) / 2.00 pm (EDT)

Click on the link to register: adc.expert/trph222-webinar

Netherlands-based Synthon Biopharmaceuticals, a biopharmaceutical research, and development company creating innovative ...
04/25/2020
Netherlands Based Precision Medicines Developer Relaunches as Byondis » ADC Review

Netherlands-based Synthon Biopharmaceuticals, a biopharmaceutical research, and development company creating innovative precision medicines including the anti-HER2 investigational antibody-drug conjugate (ADC) [vic-]trastuzumab duocarmazine, previously known as SYD985 for the treatment breast cancer, has been relaunched as Byondis.

» ADC Review Synthon Biopharmaceuticals, developing trastuzumab duocarmazine (SYD985,) relaunched as Byondis.

The U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan* (Trodelvy™; Immunomedics) for the treatm...
04/25/2020
FDA Grants Accelerated Approval for Sacituzumab Govitecan in Metastatic Triple-negative Breast Cancer » ADC Review

The U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan* (Trodelvy™; Immunomedics) for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease.

FDA Grants Accelerated Approval for Sacituzumab Govitecan in Metastatic Triple-negative Breast Cancer » ADC Review

With the FDA’s decision earlier this week to approve sacituzumab govitecan (Trodelvy™; Immunomedics) for the treatment o...
04/25/2020
Sign Up | LinkedIn

With the FDA’s decision earlier this week to approve sacituzumab govitecan (Trodelvy™; Immunomedics) for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease, the number of approved and commercially available ADC has grown to eight, making ADCs a powerful class of therapeutic agents in oncology and hematology.

To stay up to date, join the LinkedIn group of ADC Review | Journal of Antibody-drug Conjugates at https://lnkd.in/g3agyJA

500 million+ members | Manage your professional identity. Build and engage with your professional network. Access knowledge, insights and opportunities.

03/02/2020
American Society of Clinical Oncology

American Society of Clinical Oncology

Get ready for #ASCO20! Learn about the latest advances and issues concerning cancer care. This year’s new interactive style includes shorter presentations and session formats designed to enhance engagement.

01/27/2020
Stand Up To Cancer

Stand Up To Cancer

We’re live from the SU2C Summit discussing an overview for cancer research and what we can look forward to in the future. Featuring: John D. Carpten, PhD and Roderic I. Pettigrew, MD, PhD.

CPhI
01/11/2020
CPhI

CPhI

Join us at the only event in North America with the entire pharma supply chain under one roof! Network, source, learn and innovate May 5-7, 2020 at the Pennsylvania Convention Center, Philadelphia.

COPE: Promoting integrity in scholarly research and its publication
01/02/2020
COPE: Promoting integrity in scholarly research and its publication

COPE: Promoting integrity in scholarly research and its publication

A study in BMC Medicine found that the use of an online CONSORT-based Peer Review Tool (COBPeer) by trained early career researchers compared to usual peer review processes resulted in better detection of inadequate reporting in RCTS and suggests that using two-step peer review process could improve the quality of reporting. http://ow.ly/erPU50xAWGb

CPhI
11/19/2019
CPhI

CPhI

Acting as a business facilitator, CPhI South East Asia 2020 attracts pharmaceutical suppliers, buyers and distributors for 3 days of sourcing, networking and market updates, while onsite industry associations give businesses like yours hands on advice around how to enter the market and register products.

The number of antibody-drug conjugates entering the clinic is rapidly growing. While this may be the case of HER2-target...
11/15/2019
Rapid Advances in the Development of Novel ADCs Targeting B7-H3 and TROP2 » ADC Review

The number of antibody-drug conjugates entering the clinic is rapidly growing. While this may be the case of HER2-targeting ADCs, growth has especially been noted the development of ADC-targeting B7-H3 and TROP2.

https://www.adcreview.com/editorial/rapid-advances-in-the-development-of-novel-adcs-targeting-b7-h3-and-trop2/

Rapid Advances in the Development of Novel ADCs Targeting B7-H3 and TROP2 » ADC Review

Attending #WorldADC in SanDiego, CA this week? Download @ADCBIO 's new brochure designed to give you an overview of the ...
10/08/2019

Attending #WorldADC in SanDiego, CA this week? Download @ADCBIO 's new brochure designed to give you an overview of the company's Development, Manufacturing and Analytical Services + expertise. Click: https://adc.expert/2MtaxC0

ADC Directory, A Guide to the World of Antibody-drug Conjugates
10/02/2019

ADC Directory, A Guide to the World of Antibody-drug Conjugates

Design of Experiments (DoEs) are a specific application of statistical techniques to enable rapid and robust development. Those techniques can be directed towards factor screening or process robustness depending on the specific needs of the project phase. Often these experiments result in a stronger process understanding, while requiring less time and fewer material resources. Watch the Presentation On Demand.

https://adc.expert/NovasepDOE

Address


Alerts

Be the first to know and let us send you an email when ADC Review / Journal of Antibody-drug Conjugates posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to ADC Review / Journal of Antibody-drug Conjugates:

Videos

About ADC Review

ADC Review / Journal of Antibody-drug Conjugates is a new, hybrid, open access, peer reviewed journal designed to bring together the entire span of researchers and scientists from academia, the life sciences and pharmaceutical industry involved in the growing field of Antibody-drug Conjugates (ADCs).

In addition to original research and review articles, the Journal provides its audience with timely news, information and resources from around the world in all areas of Antibody-drug Conjugates development.

ADC Review / Journal of Antibody-drug Conjugates is published by InPress Media Group.

The full publication is available at http://www.adcreview.com.

Nearby health & beauty businesses